Abstracts tagged "Disease Activity"

Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Test (Vectra^® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic
Wanying Li¹, DJ Haney¹, Guy Cavet¹, Thomas W. Huizinga², Eric H. Sasso¹ and A. H. M. van der Helm-van Mil³, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…
Abstract Number: 1357 • 2013 ACR/ARHP Annual Meeting
Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs
T. Martijn Kuijper¹, Hong Xiong², A.E.a.M. Weel³, A.H. Gerards⁴, Jendé van Zeben⁵, P.H.P. de Jong⁶, Ilja Tchetverikov⁷, P.B.J. de Sonnaville⁸, M.V. Krugten⁹, B.A. Grillet¹⁰, Jolanda J. Luime² and Johanna M.W. Hazes¹¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ³Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁸Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ¹⁰Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: To explore the effect of psychosocial factors on the Disease Activity Score (DAS) and its components in early arthritis patients three months after initiating…
Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting
Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Yoon-Kyoung Sung^1,2, Kazuki Yoshida^2,3, Femke H.M. Prince^2,4, Michelle A. Frits², Jung-Yoon Choe⁵, Won Tae Chung⁶, Jisoo Lee⁷, Eun-Mi Koh⁸, Dae-Hyun Yoo⁹, Simon M. Helfgott², Nancy A. Shadick¹⁰, Michael E. Weinblatt¹¹, Sang-Cheol Bae¹ and Daniel H. Solomon², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁴Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁷Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ¹¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…
Abstract Number: 380 • 2013 ACR/ARHP Annual Meeting
Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease
Ryosuke Hanaoka^1,2, Kazuhiro Kurasawa³, Ayae Tanaka⁴ and Harutsugu Okada⁵, ¹Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Japan, ²Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Tochigi, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan, ⁵Clinical Immunology, Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects not only joints but also many organs. RA causes vascular damages to contribute to…
Abstract Number: 2569 • 2013 ACR/ARHP Annual Meeting
Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis
Michal Tomcik¹, Lucie Andres Cerezo¹, Simona Skacelova², Martin Komarc³, Radim Becvar¹, Mariam Grigorian⁴, Joerg HW Distler⁵ and Ladislav Senolt¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark, ⁵Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that S100A4 is overexpressed in scleroderma (SSc) skin, fibroblasts and preclinical models of SSc in a TGF-β dependent manner. Furthermore,…
Abstract Number: 2251 • 2013 ACR/ARHP Annual Meeting
Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry
William G. Bensen¹, Algis V Jovaisas², J. Carter Thorne³, Philip Baer⁴, Majed M. Khraishi⁵, Sanjay Dixit⁶, Denis Choquette⁷, Michael Starr⁸, Isabelle Fortin⁹, Dalton E. Sholter¹⁰, Emmanouil Rampakakis^11,12, John S. Sampalis^11,12, Francois Nantel¹³, Allen J. Lehman¹⁴, May Shawi¹⁵ and Susan M. Otawa¹⁴, ¹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸Montreal General Hospital, Montreal, QC, Canada, ⁹Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹⁰Rheumatology Associates, Edmonton, AB, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended…
Abstract Number: 1779 • 2013 ACR/ARHP Annual Meeting
A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis
Li Alemo Munters^1,2, Ingela M. Loell³, Joan Raouf⁴, Maryam Dastmalchi³, Eva Lindroos⁵, Christina Ottosson⁶, Yi-Wen Chen⁷, Annemarie F van Delden⁸, Mona Esbjörnsson⁹, Marina Korotkova¹⁰, Helene Alexanderson¹¹, Kanneboyina Nagaraju¹² and Ingrid E. Lundberg¹³, ¹Department of Medicine, Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Physiotherapy, Rheumatology Unit, Karolinska University Hospital in Solna, Stockholm, Sweden, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁷Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, ⁸Department of Medicine,, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁹Department of Physiology, Karolinska Institutet, Huddinge, Sweden, ¹⁰Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ¹¹Department of Neurobiology, Care Science and Society, Division of Physiotherapy, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, ¹²Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ¹³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: This pilot study is a hypothesis-driven exploratory part of a larger randomized controlled trial evaluating effects of a supervised 12-week endurance exercise program (EG)…
Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Eimear Savage¹, David McCormick¹, Stephen McDonald¹, Michael Stevenson², Owen Moore³ and Andrew Cairns⁴, ¹Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, ²Medical Statistics, Centre for Public Health., Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT12 6BJ, Northern Ireland, ³Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁴Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom
Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population. Patients often report increasing joint pain with…
Abstract Number: 942 • 2013 ACR/ARHP Annual Meeting
CXCL13 Is a Marker Of Joint Involvement In Early Rheumatoid Arthritis
Stinne Greisen¹, Tue Rasmussen¹, Karen Schelde¹, Kristian Stengaard-Pedersen², Merete Lund Hetland³, Kim Hørslev-Petersen⁴, Bent Deleuran⁵ and Malene Hvid⁶, ¹Dept of Biomedicine, Aarhus University, Aarhus, Denmark, ²Arhus University Hospital, Aarhus, Denmark, ³Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁴Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: CXCL13 is central in the formation of lymphoid follicles in secondary and tertiary lymphoid tissue. It attracts CXCR5-expressing B cells and follicular helper T…
Abstract Number: 392 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a major comorbidity in patients (pts) with rheumatoid arthritis (RA). We explored variations in the prevalence of cardiovascular (CV) risk…
Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…
Abstract Number: 2256 • 2013 ACR/ARHP Annual Meeting
Analysis of the Factors That Contribute to the Differences Between DAS28-ESR and DAS28-CRP
Toshihiro Matsui¹, Hirotaka Tsuno², Jinju Nishino³, Yoshiaki Kuga⁴, Atsushi Hashimoto⁵ and Shigeto Tohma⁶, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ²Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Wakaba Hospital, Saitama, Japan, ⁵Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: It is widely accepted that the remission rate of DAS28-CRP is larger than that of DAS28-ESR, SDAI, and CDAI in patients with rheumatoid arthritis.…
Abstract Number: 1787 • 2013 ACR/ARHP Annual Meeting
Does Age At Disease Onset Influence Disease Activity and Function In Rheumatoid Arthritis Patients? Results From The Ontario Best Practices Research Initiative (OBRI) Registry
Thanu Nadarajah¹, Binu Jacob², Pooneh Akhavan³, Bindee Kuriya⁴, Edward C. Keystone⁵ and Claire Bombardier⁶, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The population of elderly individuals with rheumatoid arthritis (RA) is increasing. The aim of this study was to assess whether age at disease onset…
Abstract Number: 1361 • 2013 ACR/ARHP Annual Meeting
Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort
Mami Tamai^1,2, Yoshikazu Nakashima³, Junko Kita⁴, Ayuko Takatani⁴, Ayako Nishino³, Takahisa Suzuki³, Yoshiro Horai³, Akitomo Okada⁵, Shin-ya Kawashiri^3,6, Naoki Iwamoto³, Kunihiro Ichinose³, Kazuhiko Arima⁶, Hideki Nakamura³, Tomoki Origuchi⁷, Masataka Uetani⁸, Katsumi Eguchi⁹ and Atsushi Kawakami³, ¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ²Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Prognosis of the patients with rheumatoid arthritis (RA) nowadays is supposed to become better by treat-to-target (T2T) strategy. Osteitis determined by magnetic resonance imaging…
Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting
Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Jadwiga Bienkowska³, Andrea Dearth⁴, Norm Allaire⁵ and Ann Ranger⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].